This company has been marked as potentially delisted and may not be actively trading. NASDAQ:GTXI GTX (GTXI) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisHeadlinesTrendsBuy This Stock About GTX Stock (NASDAQ:GTXI) 30 days 90 days 365 days Advanced Chart Get GTX alerts:Sign Up Key Stats Today's Range$0.53▼$0.5350-Day Range$1.20▼$7.2052-Week Range$0.74▼$25.60VolumeN/AAverage Volume390,540 shsMarket Capitalization$12.66 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It develops selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer. The company's SARM product candidate is the enobosarm GTx-024, a Phase II proof-of-concept clinical trial for patients with androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee. Read More Receive GTXI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GTX and its competitors with MarketBeat's FREE daily newsletter. Email Address GTXI Stock News HeadlinesWIN Alienware 15 R3 laptop with GTX 1070July 4, 2025 | msn.comRazer Blade Stealth (Kaby Lake) With Core and GTX 1070 (4k60p)July 3, 2025 | msn.com$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal. | Brownstone Research (Ad)GTX 1050 Ti vs GTX 1050 in Metro Last LightJuly 2, 2025 | msn.comThe Last of Us Part I : GTX 1060 + i3 9100F | 1080pJuly 1, 2025 | msn.comAssetto Corsa : GTX 1050 Ti - Pentium G4560July 1, 2025 | msn.comNvidia to Drop Driver Support for GTX Series GPUs Sometime in 2026July 1, 2025 | msn.comNvidia’s legendary GeForce GTX 10-series cards might lose support soonJuly 1, 2025 | msn.comSee More Headlines GTXI Stock Analysis - Frequently Asked Questions How were GTX's earnings last quarter? GTx, Inc. (NASDAQ:GTXI) released its earnings results on Thursday, November, 15th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by $0.09. What other stocks do shareholders of GTX own? Based on aggregate information from My MarketBeat watchlists, some other companies that GTX investors own include Corbus Pharmaceuticals (CRBP), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), SELLAS Life Sciences Group (SLS), Verastem (VSTM), Bristol Myers Squibb (BMY) and Catalyst Pharmaceuticals (CPRX). Company Calendar Last Earnings11/15/2018Today7/08/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:GTXI CIK1260990 Webwww.gtxinc.com Phone901-523-9700FaxN/AEmployees21Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$38.42 million Net MarginsN/A Pretax MarginN/A Return on Equity-104.19% Return on Assets-86.42% Debt Debt-to-Equity RatioN/A Current Ratio12.39 Quick Ratio12.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.09 per share Price / Book0.48Miscellaneous Outstanding Shares24,050,000Free FloatN/AMarket Cap$12.66 million OptionableNot Optionable Beta2.22 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:GTXI) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredInstant Cash (in 4 clicks)Since 1973, Wall Street has quietly used a strange little pricing quirk to cash flow billions. Now, for the...Awesomely, LLC | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GTx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GTX With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.